Brensocatib

Generic Name: Brensocatib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₄N_₄O_₄

CAS Number: 1802148-05-5

Unique Ingredient Identifier: 25CG88L0BB

Background: Brensocatib is under investigation in clinical trial NCT03218917 (Assessment of INS1007 in Subjects With Non-cystic Fibrosis Bronchiectasis).

Indication: 用于非囊性纤维化支气管扩张症（NCFBE）成人患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Brensocatib
Drug: Placebo

First Posted Date: 2024-11-13

Last Posted Date: 2024-12-19

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 204

Registration Number: NCT06685835

Locations: 🇺🇸
USA002, Baton Rouge, Louisiana, United States

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Brensocatib

First Posted Date: 2023-12-21

Last Posted Date: 2024-01-22

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 20

Registration Number: NCT06178783

Locations: 🇺🇸
USA001, Dallas, Texas, United States

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Phase 2

Recruiting

Conditions: Chronic Rhinosinusitis Without Nasal Polyps

Interventions: Drug: Placebo
Drug: Brensocatib
Drug: Mometasone furoate nasal spray (MFNS)

First Posted Date: 2023-08-28

Last Posted Date: 2024-11-20

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 270

Registration Number: NCT06013241

Locations: 🇺🇸
USA036, Chicago, Illinois, United States
🇺🇸
USA003, New Albany, Indiana, United States
🇺🇸
USA035, Mandeville, Louisiana, United States

and more 99 locations

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Brensocatib
Drug: Clarithromycin

First Posted Date: 2023-07-28

Last Posted Date: 2023-12-11

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 22

Registration Number: NCT05965570

Locations: 🇺🇸
USA001, Dallas, Texas, United States

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Brensocatib
Drug: Rifampin
Drug: Esomeprazole

First Posted Date: 2023-04-24

Last Posted Date: 2023-08-21

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 32

Registration Number: NCT05826574

Locations: 🇺🇸
USA001, Dallas, Texas, United States

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Brensocatib

First Posted Date: 2023-01-06

Last Posted Date: 2023-04-18

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 28

Registration Number: NCT05673603

Locations: 🇺🇸
USA003, Tampa, Florida, United States
🇺🇸
USA001, San Antonio, Texas, United States
🇺🇸
USA002, Orlando, Florida, United States

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Brensocatib

First Posted Date: 2022-08-26

Last Posted Date: 2023-07-19

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 30

Registration Number: NCT05517525

Locations: 🇺🇸
USA002, Rialto, California, United States
🇺🇸
USA003, Orlando, Florida, United States
🇺🇸
USA001, San Antonio, Texas, United States

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Brensocatib
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2022-05-02

Last Posted Date: 2023-03-27

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 48

Registration Number: NCT05355935

Locations: 🇺🇸
USA001, Madison, Wisconsin, United States

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Conditions: Non-Cystic Fibrosis Bronchiectasis

First Posted Date: 2022-04-25

Last Posted Date: 2024-11-26

Lead Sponsor: Insmed Incorporated

Registration Number: NCT05344508

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Brensocatib
Drug: Placebo

First Posted Date: 2021-10-25

Last Posted Date: 2023-11-01

Lead Sponsor: Insmed Incorporated

Target Recruit Count: 29

Registration Number: NCT05090904

Locations: 🇺🇸
USA001, Gainesville, Florida, United States
🇺🇸
USA016, Augusta, Georgia, United States
🇺🇸
USA006, Cleveland, Ohio, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy